Biotech Values

[jmkobers]

Who's selling the CD?

A one drug pony would seem to be at a disadvantage in the hospital setting, so Revance wouldn't send in their own freshly minted and expensive reps to do that just that one thing, right? Or would they and the street is sniffing out more potential dilution, a costly launch, and, together with disappointing sales to date, results in 22 and change pps? If you expect a partner, at what terms? Could the terms be potentially good enough to make a raise less likely, perhaps even totally unnecessary?